Bremelanotide

Drug Profile

Bremelanotide

Alternative Names: PT-141; RekyndaTM

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator University of Arizona
  • Developer Palatin Technologies; Simons Foundations
  • Class Cyclic peptides; Erectile dysfunction therapies; Hypothalamic hormones; Melanocyte-stimulating hormones
  • Mechanism of Action Melanocortin type 4 receptor agonists; Melanocyte stimulating hormone stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase III Female sexual dysfunction
  • Phase II Cognition disorders
  • No development reported Erectile dysfunction
  • Discontinued Haemorrhagic shock; Vascular disorders

Most Recent Events

  • 09 Jan 2017 Bremelanotide licensed to AMAG Pharmaceuticals in North America
  • 09 Jan 2017 Palatin completes two phase III trials in Female sexual dysfunction in USA and Canada
  • 01 Nov 2016 Safety and efficacy data from the phase III Reconnect trials in Female sexual dysfuction released by Palatin Technologies
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top